Replimune Group, Inc.

XNASHealth care

Last traded price · USD

$20.79

+0.48%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:31 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $20.69
Volume: 29
Day's high: —
Day's low: —

In brief

Replimune Group, Inc. is a health care company listed on Nasdaq, valued at about $1.97B.
Its shares closed at $20.69 on 4 Nov 2026, up 130.7% over the past year.
From India you can buy REPL in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Replimune Group, Inc. (REPL) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole REPL share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade REPL options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

2.7% below its 52-week high
Closed at $20.69 on 4 Nov 2026: 2.7% below the 52-week high of $21.26 (3 Nov 2026) and 1279.3% above the low of $1.50 (13 Apr 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Ahead of SPY and its sector fund XLV over 1 year
1 month: +56.2% (SPY −1.6%, XLV +13.5%). 3 months: +74.9% (SPY −0.4%, XLV +15.5%). 1 year: +130.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: REPL, SPY and XLV · as of 4 Nov 2026
12.7 days to cover short interest
23.2M shares were sold short at the 15 Oct 2026 settlement, 24.4% of the 94.8M shares outstanding; covering them would take 12.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 3.2× its 30-session average on 2 Nov 2026
2 Nov 2026 volume of 7.7M shares was 3.2× the average of the 30 sessions before it (2.4M), as the price rose 10.7%. SPY traded 1.2× its own average that session.
Daily volume against a 30-session baseline · as of 2 Nov 2026
RSI(14) at 81.9, 70 or above
The 14-session relative strength index closed at 81.9 on 4 Nov 2026, its 6th session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+56.2%

6 months+620.9%

1 year+130.7%

5 years−37.9%

Newswire

About

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Website

Notable moves

July 31, 2026
+107.02%
October 20, 2025
+98.78%
July 30, 2025
+101.33%

Newswire

About

Website

Notable moves

July 31, 2026
+107.02%
October 20, 2025
+98.78%
July 30, 2025
+101.33%

Replimune Group, Inc.

XNASHealth care

Last traded price · USD

$20.79

+0.48%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:31 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $20.69
Volume: 29
Day's high: —
Day's low: —

In brief

Replimune Group, Inc. is a health care company listed on Nasdaq, valued at about $1.97B.
Its shares closed at $20.69 on 4 Nov 2026, up 130.7% over the past year.
From India you can buy REPL in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Replimune Group, Inc. (REPL) shares from India?

Do I need the price of a whole REPL share to invest?

How much can I invest in US stocks in a year?

Can I trade REPL options or futures?

Insights

Quotes run fifteen minutes behind.

2.7% below its 52-week high
Closed at $20.69 on 4 Nov 2026: 2.7% below the 52-week high of $21.26 (3 Nov 2026) and 1279.3% above the low of $1.50 (13 Apr 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Ahead of SPY and its sector fund XLV over 1 year
1 month: +56.2% (SPY −1.6%, XLV +13.5%). 3 months: +74.9% (SPY −0.4%, XLV +15.5%). 1 year: +130.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: REPL, SPY and XLV · as of 4 Nov 2026
12.7 days to cover short interest
23.2M shares were sold short at the 15 Oct 2026 settlement, 24.4% of the 94.8M shares outstanding; covering them would take 12.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 3.2× its 30-session average on 2 Nov 2026
2 Nov 2026 volume of 7.7M shares was 3.2× the average of the 30 sessions before it (2.4M), as the price rose 10.7%. SPY traded 1.2× its own average that session.
Daily volume against a 30-session baseline · as of 2 Nov 2026
RSI(14) at 81.9, 70 or above
The 14-session relative strength index closed at 81.9 on 4 Nov 2026, its 6th session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+56.2%

6 months+620.9%

1 year+130.7%

5 years−37.9%

Newswire

About

Website

Notable moves

July 31, 2026
+107.02%
October 20, 2025
+98.78%
July 30, 2025
+101.33%

Newswire

About

Website

Notable moves

July 31, 2026
+107.02%
October 20, 2025
+98.78%
July 30, 2025
+101.33%

Replimune Group, Inc.

Replimune Group, Inc. in brief

2.7% below its 52-week high

Ahead of SPY and its sector fund XLV over 1 year

12.7 days to cover short interest

Volume 3.2× its 30-session average on 2 Nov 2026

RSI(14) at 81.9, 70 or above

Replimune Group, Inc.

Replimune Group, Inc. in brief

2.7% below its 52-week high

Ahead of SPY and its sector fund XLV over 1 year

12.7 days to cover short interest

Volume 3.2× its 30-session average on 2 Nov 2026

RSI(14) at 81.9, 70 or above